The second quarter of 2026 marks an unprecedented capital market boom for Taiwan's healthcare sector, with 11 biotechnology and medical technology companies scheduled to enter the capital markets. Backed by the implementation of the Regenerative Medicine Dual Laws, the government’s "Healthy Taiwan Deep-Rooting Plan," and the upcoming Bio Taiwan Committee (BTC) events in July, market momentum is surging.

• Key Clinical & Technology Debutants:
• Hanchor  (漢康-KY) and AP Biosciences  (圓祥生技) are capturing significant institutional attention with advanced immunotherapy and bispecific antibody platforms, both possessing high-value international out-licensing catalysts worth hundreds of millions of USD expected in H2 2026.
• aetherAI (雲象科技), an AI-driven digital pathology pioneer backed by Quanta Computer, is scheduled to list on the Taiwan Innovation Board (TIB) on May 20, 2026, at an issue price of NT$25. Driven by global digital transformation trends, its 2025 revenue surged 90% YoY across Taiwan, Japan, and the US markets.
• Secondary Wave and Pipeline: Regenerative medicine player HeXun Biosciences (和迅), carotenoid developer Allied Biotech Corporation (立弘), and Hydron Group’s medical-grade collagen subsidiary Horien Biochemical Technology (海昌生技) are slated for Taipei Exchange (TPEx) listings in June. Furthermore, TAHO Pharmaceuticals (泰合生技) passed its listing review in early May targeting a Q3 debut for its oral soluble film formulation TAH3311, while digital health platform H2U (永悅健康) is tracking toward a Q3 TIB listing.
• Record-Breaking Projections: Following 15 listings in 2024 and 10 in 2025, investment analysts project that total biopharma and medtech listings could hit a historic high of over 20 companies in 2026, successfully resisting capital diversion toward pure-play hardware AI stocks.

Resource:生技股邁入掛牌高峰期